SFU
XLRN

Stonehage Fleming (UK)’s Acceleron Pharma XLRN Stock Holding History

Stonehage Fleming (UK)’s Portfolio XLRN Stock Details XLRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-518
Closed -$20K – 274
2014
Q4 		$20K Buy
+518
New +$18.1K 0.01% 253
2014
Q3 		– Sell
-764
Closed -$26K – 347
2014
Q2 		$26K Sell
764
-454
-37% -$15.2K 0.01% 222
2014
Q1 		$42K Sell
1,218
-597
-33% -$26.9K 0.02% 265
2013
Q4 		$72K Buy
+1,815
New +$43.8K 0.03% 189

Other funds holding XLRN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
PVMCI
Polaris Venture Management Co IV Boston, Massachusetts $62.4M AUM 33.04% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
ORI
Oak Ridge Investments Chicago, Illinois $1.51B AUM 37.25% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
QF
QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return

Stonehage Fleming (UK)'s XLRN Position: Q1 2015 in Review

Stonehage Fleming (UK) sold out of Acceleron Pharma (XLRN) in Q1 2015, closing a stake of 518 shares — an estimated $20K sold.

Stonehage Fleming (UK) first reported a position in XLRN in Q4 2013 and held it in 4 quarters. The position peaked at $72K in Q4 2013. 115 funds tracked by Wall St. Rank hold XLRN as of Q1 2015.

  • Stonehage Fleming (UK) reported no remaining Acceleron Pharma position as of Q1 2015 after selling out during the quarter.
  • Stonehage Fleming (UK) sold 518 Acceleron Pharma shares in Q1 2015, an estimated $20K.
  • Stonehage Fleming (UK) first reported a position in Acceleron Pharma in Q4 2013 and held it in 4 quarters.
  • Stonehage Fleming (UK)'s Acceleron Pharma position peaked at $72K in Q4 2013.
  • 115 funds tracked by Wall St. Rank held Acceleron Pharma as of Q1 2015.

Based on Stonehage Fleming (UK)'s 13F filing for Q1 2015, filed 11 Oct 2019.